Clinical trials: Hyperuricemia
Coronary Artery Disease
the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia
The purpose of this study is to investigate the effects of febuxostat on coronary plaque volume in patients with chronic stable angina and hyperuricemia.
- Trial name
- NCT02279342
- Testing
- Febuxostat
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Yokohama City University Medical Center
Tumor Lysis Syndrome, Cancer
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
This is a randomized, multi-center, open-label, parallel group study with three arms: Rasburicase alone Rasburicase followed by Allopurinol Allopurinol alone The primary objective is to compare the adequacy of control of plasma…
- Conditions
- Tumor Lysis Syndrome, Cancer, Hyperuricemia
- Trial name
- NCT00230178
- Testing
- Rasburicase (SR29142), Allopurinol
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Sanofi
Gout; Hyperuricemia, Gout Flare
Developing A Gout Action Plan in Primary Care Setting in Singapore
The goal of this clinical trial is to develop a gout action plan in primary care setting in Singapore among adult patients with gout, and to learn if the gout action plan can improve gout control.
- Conditions
- Gout; Hyperuricemia, Gout Flare, Gout Chronic
- Trial name
- NCT07061587
- Testing
- Gout action plan
- Where
- Singapore
- Volunteers
- 72 people
- Sponsor
- SingHealth Polyclinics
Gout
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the…
- Trial name
- RELEASE (NCT07280156)
- Testing
- PRX-115, Methotrexate (MTX)
- Where
- 35 sites in United States, Georgia and 1 more
- Volunteers
- 150 people
- Sponsor
- Protalix
Chronic Heart Failure, Hyperuricemia
Allopurinol in Chronic Heart Failure
The purpose of this study is to discover whether the inhibition of the xanthine oxidase with allopurinol leads to a reduction of the production of oxygen free radicals in patients with CHF and thereby improves characteristics of…
- Trial name
- NCT00997542
- Testing
- Allopurinol
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- National Heart and Lung Institute
Lymphoma
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
Primary Objective: To evaluate safety of rasburicase in pediatric patients with NHL and AL Secondary Objective: To assess efficacy of rasburicase for prevention and treatment of hyperuricemia
- Trial name
- RAISE (NCT04349306)
- Testing
- RASBURICASE SR29142
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sanofi
Hyperuricemia
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previously treated or not with…
- Trial name
- GRAAL2 (NCT00664144)
- Testing
- Rasburicase (SR29142)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Sanofi
Chronic Kidney Disease
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6…
- Trial name
- SAPPHIRE (NCT03990363)
- Testing
- Verinurad, Allopurinol
- Where
- 165 sites in United States, Czechia and 10 more
- Volunteers
- 861 people
- Sponsor
- AstraZeneca
Uric Acid Concentration, Serum, Quantitative Trait Locus 7
Effect of Losartan or Eprosartan on Fructose Hyperuricemia
Hyperuricemia is seen in about 20% of adults in the general population, Chronic hyperuricemia, frequently manifesting as the gout, is a well-known risk factor of joint damage but has been also linked to a variety of other…
- Trial name
- metabolic (NCT04954560)
- Testing
- losartan and eprosartan
- Volunteers
- 16 people
- Sponsor
- Medical University of Lodz
Asymptomatic Hyperuricemia
A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
The main purpose To evaluate the safety and tolerability of pegloticase in subjects with asymptomatic hyperuricemia by single intravenous infusion at different doses, and to provide a basis for multiple doses of Pegloticase in…
- Trial name
- NCT05302388
- Testing
- SIBP-R002, Dexamethasone or Methyl prednisolone, Diphenhydramine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Institute Of Biological Products
Renal Impairment
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.
- Trial name
- NCT01082640
- Testing
- Febuxostat
- Where
- 58 sites in United States
- Volunteers
- 96 people
- Sponsor
- Takeda
Hyperuricemia, Gout
Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
The purpose of this Phase I study is to evaluate the safety and tolerability of ALLN-346 in in normal healthy volunteers, in an ascending dose design.
- Trial name
- MAD (NCT04829435)
- Testing
- ALLN-346
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Allena Pharmaceuticals
Hyperuricemia
A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
The objective of the study is to assess the Safety and Efficacy of SHR4640 and Febuxostat in patients with Hyperuricemia.
- Trial name
- NCT04180982
- Testing
- SHR4640 dose1 plus Febuxostat dose1, SHR4640 dose1 plus Febuxostat dose2, SHR4640 dose2 plus Febuxostat dose3
- Volunteers
- 84 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gout
Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers
This study was designed to compare and evaluate the pharmacokinetic characteristics of febuxostat after single oral administration of TMX-67 (test drug) and Feburic® tablet in healthy adults; and to evaluate safety and tolerance…
- Trial name
- NCT01563432
- Testing
- Feburic®, TMX-67
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Hyperuricemia
Effect of the Consumption of a Combination of Plant Extracts (BSL_EP026) on Serum Uric Acid.
The objective of this study is to evaluate the effect of the combination of a combination of plant extracts (BSL_EP026) on blood and urine uricemia levels in individuals with levels at the limit of the values considered normal or…
- Trial name
- NCT04165499
- Testing
- Combination of Plant Extracts (BSL_EP026), Control
- Where
- Spain
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Gout, Hyperuricemia
Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
This is a Phase II, Multicenter, Randomized, Double-blind, Placebo controlled, Multiple Dose study to evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients with Hyperuricemia.
- Trial name
- NCT04040816
- Testing
- SAP-001
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Shanton Pharma Co., Ltd.
Hyperuricemia, Gout
Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout
The purpose of this study is to determine whether levotofisopam is safe and effective in the treatment of hyperuricemia and gout.
- Trial name
- NCT01519687
- Testing
- levotofisopam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pharmos
Hypertension
Effect of Febuxostat on Blood Pressure
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with…
- Trial name
- NCT01496469
- Testing
- Febuxostat
- Where
- 45 sites in United States
- Volunteers
- 121 people
- Sponsor
- Takeda
Atrial Fibrillation, Hyperuricemia
Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation
To clarify the predictive effects of uric acid and superoxide dismutase as biomarkers of oxidative stress on atrial fibrillation, and to provide greater value for the diagnosis and prediction of atrial fibrillation.
- Trial name
- NCT06119802
- Testing
- atrial fibrillation
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Yinglong Hou
Hyperuricemia
Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia
An observational study to evaluate the prevalence of US changes of gout in the joints and tendons of patients with different degrees of asymptomatic hyperuricemia.
- Trial name
- NCT02502565
- Testing
- Uric acid level
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Washington D.C. Veterans Affairs Medical Center